Adenosine is an inhibitory neuromodulator in several brain regions. In the nucleus tractus soUtarius (NTS), however, adenosine exerts excitatory cardiovascular effects. The purpose of the present study was to elucidate the involvement of other endogenous mechanisms that could contribute to the final hemodynamic response to adenosine in this nucleus. In normotensive Sprague-Dawley rats, intra-NTS microinjection of adenosine (23 nmol/60 nl) decreased blood pressure and heart rate. These effects were blocked by prior administration of the specific adenosine receptor antagonist l,3-dipropyl-8-p-sulfophenylxanthine (0.92 nmol) and by the two glutamate receptor antagonists kynurenic acid and glutamic diethylester. The specificity of the adenosine-glutamate interaction in the NTS was demonstrated with adrenergic and angiotensin receptor antagonists that did not affect the adenosine response and by experiments with glutamate receptor antagonists that did not affect nicotine actions in the NTS. Furthermore, an increase in glutamate levels was demonstrated during perfusion of adenosine through a microdiatysis probe in the NTS of anesthetized rabbits. These findings indicate that adenosine increases the release of glutamate in the NTS and, thus, are at variance with the concept of a "universal" inhibitory effect of adenosine in the central nervous system. (Hypertension 1991;18:494-502)
T he endogenous nucleoside adenosine has been studied for its potential role as neuromodulator in a number of autonomic functions. 1 Recent evidence has indicated that adenosine can also affect cardiovascular function within the central nervous system (CNS). 2 - 4 Initial support came from studies that indicated the presence of adenosine immunoreactivity 5 and receptors 6 within specific neuronal cell groups of the brain stem and spinal cord. In addition, other groups have characterized the presence of both an energy-dependent high affinity uptake system for adenosine 7 - 8 and immunocytochemical localization of adenosine deaminase 9 in relevant autonomic brain nuclei.
The highest density of adenosine uptake sites in the CNS has been observed in the nucleus tractus solitarius (NTS). 8 Neuronal cell groups in this nucleus regulate reflex cardiovascular activity, 10 and this raises the possibility that adenosine is involved in central cardiovascular function. In earlier experiments, we and others characterized the potent cardiovascular effects of purinergic activation in the NTS. 2 - 4 It might have been expected that activation of purinergic receptors in this nucleus would raise blood pressure as adenosine is considered an inhibitory neuromodulator.
11
- 14 Previously, it has been observed that suppression of NTS action by microinjection of putative inhibitory neurotransmitters, 15 " 17 or local anesthetics, 18 results in a hypertensive response. Paradoxically, in this nucleus, adenosine decreases blood pressure, heart rate, 2 -1 and renal sympathetic nerve activity. 19 These effects are compatible with activation (rather than inhibition) of neuronal cells in the NTS in which either electrical stimulation 20 or microinjection of excitatory substances 21 -22 results in decreased sympathetic tone, hypotension, and bradycardia. The cardiovascular effects of adenosine in the NTS are strikingly similar to those of the excitatory amino acid glutamate. When microinjected into the caudal part of the pars medialis of the NTS, both substances decrease blood pressure, heart rate, and renal sympathetic nerve activity.
2 " 3 - 21 Furthermore, both adenosine and glutamate receptor antagonists inhibit baroreceptor reflex activity in the NTS, and they appear to have a facilitatory role in baroreceptor reflex regulation. 4 - 21 ' 22 This raises the possibility that the excitatory cardiovascular effects of adenosine in the NTS are mediated by activation of glutamate mechanisms and this interaction could be of relevance in the reflex control of the circulation.
In the present experiments, we explored a possible adenosine-glutamate interaction by testing whether a specific adenosine receptor antagonist is able to inhibit the effects of glutamate in the NTS, and conversely, if glutamate receptor antagonists are able to inhibit the effects of intra-NTS injections of adenosine. In addition, we studied whether perfusion of adenosine into the NTS affects glutamate levels in this nucleus. The results indicate that adenosine and glutamate interact in the NTS, and this could explain the excitatory cardiovascular effects of purines in this nucleus.
Methods

Microinjection Studies
Male Sprague-Dawley rats (Sasco Sprague-Dawley, St. Louis, Mo.) weighing between 275 and 350 g were used in these studies. The rats were housed in an animal room with a 12-hour light/dark cycle and were fed rat chow and tap water ad libitum. Rats were initially anesthetized with urethane (1.0 g/kg i.p.). If adequate levels of anesthesia were not obtained or maintained (presence of a reflex withdrawal of the leg in response to a noxious stimulus in the same area or wide variations in basal blood pressure) a supplemental dose of urethane (300 mg/kg i.v.) was administered. A polyethylene cannula was placed in the femoral vein for administration of drugs, and blood pressure was measured directly through a cannula placed into the femoral artery and connected to a pressure transducer (P23ID, Gould Inc., Cleveland, Ohio) and a polygraph (RS 3800, Gould). Heart rate was monitored continuously by a tachograph preamplifier (13-4615-65, Gould).
The animals were then placed in a stereotaxic instrument (Kopf) with the head flexed downward at a 45° angle. The dorsal surface of the medulla was exposed by limited craniotomy, and the animals were allowed to rest for at least 1 hour before the experiments. For microinjections into the brain nuclei, glass cannulas were prepared (0.031 in. o.d., 0.006 in. i.d., Richland Glass Co., Richland, N.J.) with an external tip diameter of 40 fira. The cannula was connected to a Hamilton microsyringe through polyvinyl tubing. The cannulas were either filled with glutamate (2.3 nmol), adenosine (2.3 nmol), nicotine (369 pmol), the adenosine receptor antagonist 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX) (0.92 nmol), the excitatory amino acid receptor antagonists kynurenic acid (KYN) (33 nmol) or L-glutamate diethylester (GDEE) (20.8, 62.5 , and 125 nmol), yohimbine (0.5 nmol), or saralasin (0.11 nmol). The cannula was lowered into the NTS with the anteriorposterior coordinates 0.0 mm, mediolateral 0.5 mm, and vertical 0.2 mm, using the obex as reference.
For microinjection into the NTS, the drugs (except yohimbine) were dissolved in sterile saline to final concentrations in a volume not exceeding 60 nl. Although one report observed cardiovascular changes after microinjection of 0.1 y\ saline, 23 we and others have not recorded significant cardiovascular effects of similar or smaller volumes of saline in the NTS, 21   -24   -25 and therefore we used it for the control experiments. Yohimbine was dissolved in 0.01N HC1. We have previously determined that injections of relevant volumes of 0.01N HC1 had no significant effect on cardiovascular regulation after NTS injection.
In the first group of animals (n=9), the effects of intra-NTS administration of adenosine on blood pressure and heart rate were observed 10 minutes after the similar microinjection of 60 nl saline. Thirty minutes after recovery, the animals were pretreated with the adenosine receptor antagonist DPSPX, and the cardiovascular action of the same dose of adenosine was compared with that obtained after saline. In different groups of animals, a similar experimental procedure was used to study the effects of pretreatment with DPSPX on glutamate (n=12), GDEE on adenosine (n=10), GDEE on glutamate (n=9), KYN on adenosine (n=10), KYN on nicotine (n=4), yohimbine on adenosine (n=4), and saralasin on adenosine (n=4).
After completion of the experiment, 120 nl ink was injected through the cannula (for localization), and the animals were perfused with saline followed by a solution of 4% formaldehyde and finally with a 30% sucrose solution. Sections of 40 /*m of the brain stem were stained with cresyl violet and placement of the pipette tip in the NTS was verified by the histologjcal sections. Only results from those animals in which the histological sections documented adequate placement within the NTS were included for final evaluation.
Microdiafysis Studies
To study the effects of intra-NTS microinjection of adenosine on the endogenous levels of glutamate we used a microdialysis technique. New Zealand White rabbits (2.5-3.0 kg) were anesthetized with urethane (1.0 g/kg i.v., given in the dorsal marginal ear vein) and supplemented with 300-500 mg/kg if needed. This species was selected because a microdialysis probe with an active exposed portion of the membrane of 1.5 mm dialyzes the entire dorsal-ventral extent of the NTS of the rabbit. 26 In contrast a similar size probe perfuses not only the NTS but also other surrounding areas in the rat (unpublished observations from our laboratory).
The rabbits were instrumented with a cannula placed in the femoral artery for blood pressure recording and were placed in a stereotaxic frame. The head of the animal was kept in place using a rabbit adaptor head holder (Kopf 1240, Tujunga, Calif.), and the dorsal surface of the medulla was exposed removing the atlanto-occipital membrane. A microdialysis probe (1- ", 132.76 mM CT, pH 7.4) was perfused at a rate of 1 /xl/min. After implantation of the probe, a stabilization period was followed by perfusion over 60 minutes with CSF containing either no adenosine or adenosine in concentrations of 10" 6 or 10~3 M. Perfusion samples (60 /il) were collected in small volume tubes kept at 0°C before analysis. Samples were analyzed for their glutamate content using a high-performance liquid chromatography (HPLC) system (Picotag Waters system for HPLC analysis of free amino acids, Milford, Mass.) with a 1 pmol sensitivity. 27 In vitro calibration was done before and after microdialysis probe implantation. Recovery in vitro was determined by placing the probe in a container with a solution of 10" 3 M, 10" 6 M, or 10"' M of glutamate and perfusing the probe at 1 /il/min with artificial CSF. The recovery was determined using the following formula: Recovery^ vitro =concentration in the outflow solution/concentration in the medium. The recovery rate for glutamate was between 20 and 25%. For estimation of glutamate concentrations, the dialysate was mixed with the internal standard (5 fjM a-aminoadipate), reacted with o-phthaldialdehyde and after 2 minutes reaction, the sample was injected into the HPLC system. From a standard chromatogram of amino acids including the internal standard, a detector response factor for glutamate was calculated relative to the internal standard. Using this relative response factor, concentrations of glutamate were calculated from peak areas in the individual chromatograms by internal standard quantitation. A similar procedure was used to estimate the in vitro recovery rate for adenosine, which was found to be between 10% and 13%. Adenosine concentration in the in vitro samples were estimated using an HPLC method as described elsewhere. 28 
Drugs
The following drugs were used: adenosine, KYN, nicotine, [Sar 
Statistical Analysis
Results were compared by Student's paired f test for the groups evaluating control adenosine or glutamate responses (with saline pretreatment) versus the responses obtained with the same drugs in the same animal after receptor antagonist pretreatment. For the microdialysis studies, the results were compared by analysis of variance followed by a Dunnett's test for significant differences. All data are presented as mean±SEM. Differences with a value of p<0.05 were taken as significant.
Results
In agreement with our previous findings, intra-NTS administration of 2.3 nmol adenosine caused hypotension and bradycardia that was maximal at 1.5 minute and was fully recovered 20 minutes after administration. Prior microinjection of saline into the NTS did not modify the adenosine effects on blood pressure and heart rate (data not shown). However, when the second adenosine injection followed by 10 minutes the intra-NTS administration of 0.92 nmol of DPSPX, the effects of adenosine were significantly attenuated ( Figure 1A) . Peak blood pressure response to adenosine was inhibited by 86±11%.
To test whether a glutamatergic mechanism was involved in the actions of adenosine, we used the excitatory amino acid receptor antagonist KYN. There are several classes of excitatory amino acid receptors and most, if not all of them, are activated by glutamate. 29 On the other hand, KYN is a broadspectrum glutamate receptor antagonist that has been used to probe the physiological role of glutamate and other excitatory amino acids. 30 Intra-NTS injection of 33 nmol of KYN increased blood pressure (18±4 mm Hg) and decreased heart rate (38+16 beats/min). The effects of KYN on basal blood pressure and heart rate were significantly different from those of intra-NTS administration of saline (p<0.005, unpaired t test). In addition, KYN significantly inhibited the effects of the adenosine on both blood pressure and heart rate ( Figure 2 , left panel). Similar results were obtained with GDEE, another glutamate receptor antagonist. Intra-NTS administration of GDEE (125 nmol) increased basal blood pressure by 21 ±2 mm Hg and decreased heart rate by 40 ±9 beats/min (significantly different from saline values/?<0.01, by unpaired t test). The cardiovascular effects of adenosine were significantly inhibited by prior administration of GDEE ( Figure 1C ). The inhibitory effects of GDEE on adenosine cardiovascular actions were dose-dependent. After 21 and 63 nmol of GDEE, adenosine decreased blood pressure by -21 ±4 and -11 ±3 mm Hg, respectively (see also Table 1 ).
To investigate whether reciprocal interactions between purinergic systems and glutamate are present in the NTS, we tested the effects of prior DPSPX administration into this site on glutamate cardiovascular actions. Microinjection of glutamate into the NTS (2.3 nmol) evoked a similar hypotensive response but a more profound bradycardia than an equimolar dose of adenosine ( Figure IB) . Pretreatment with DPSPX (0.92 nmol) did not affect the actions on blood pressure and heart rate evoked by subsequent glutamate administration. In contrast, the hypotensive effect of glutamate in the NTS was almost completely abolished, and the heart rate effect was inhibited 85 ±12% by prior GDEE microinjection ( Figure ID ). In a different group of rats, we addressed the specificity of the adenosine-glutamate interaction using microinjections of nicotine into the NTS. Intra-NTS microinjection of nicotine had qualitative effects similar to those of glutamate and adenosine. The hypotensive (-32 ±6 mm Hg) and bradycardic responses (-33 ±10 beats/min) to nicotine were not affected by pretreatment with the glutamate receptor antagonist KYN (-42 ±3 mm Hg and -48 ±8 beats/ min, after 33 nmol of KYN, Figure 2) .
I
The possible participation of other neuromodulatory systems in the mediation of purinergic actions was explored with the use of adrenergic and angiotensin receptor antagonists. When microinjected into the NTS, the a 2 -adrenergic receptor antagonist yohimbine (0.5 nmol) modestly increases blood pressure and decreases heart rate. The subsequent cardiovascular effects of adenosine, however, were unchanged (Table 2 ). Similar lack of inhibitory effects were observed with the angiotensin receptor antagonist saralasin. Although basal blood pressure and heart rate increased after intra-NTS administration of saralasin administration, the hypotensive and bradycardic effects of adenosine were unaffected (Table 2) .
Since the adenosine receptor antagonist DPSPX was unable to alter the cardiovascular effects of glutamate, we next studied the possibility that adenosine might modulate glutamate levels in the NTS. Microdialysis is a new bioanalytical method with which it is possible to sample a number of extracellular fluid elements, including purines and excitatory amino acids. 31 Using this technique, we estimated the basal and adenosine-stimulated levels of glutamate in the NTS of anesthetized rabbits. A period of 1.5-2 hours was needed to obtain steady levels of glutamate after placement of the microdialysis probe in the NTS. Basal glutamate concentrations were 15.8±3.2 fimoUl, with relatively wide interindividual variations (range, 8.6-28.3 fimoi/l, n=5). Perfusion of the lower concentration of adenosine (10~6 M) through the microdialysis probe increased glutamate levels slightly in two animals, did not change them in one, and decreased them in the remaining two. Overall glutamate levels averaged 20.9+11.8 ^.mol/1 with this adenosine concentration (Figure 3 ). In contrast, 10~3 M adenosine increased glutamate levels to 
FIGURE 2. Bar graphs show effects of glutamate receptor antagonist kynurenic acid (KYN) on the hypotensive and bradycardic response to microinjected adenosine (ADO) or nicotine (NIC) into the nucleus tractus soUtarius (NTS) of anesthetized rats. In a group of 10 animals pretreated with intra-NTS administration of saline (SAL+ADO, open bar at the left), ADO cardiovascular effects were significantly inhibited by the prior administration of KYN (33 nmol, KYN+ADO, solid bar at the left, p<0.01). In contrast, the hypotensive and bradycardic effects of NIC were not modified by either SAL (SAL +NIC, right open bar) or by the same dose of the glutamate receptor antagonist (KYN+NIC, right solid bar, n=4). Basal blood pressure (MBP) and heart rate (HR) were 95±4 mm Hg and 334±16 beats/min for the ADO group and 87±6 mm Hg and 345±12 beats/min for the NIC group.
127.4±50.3 ^.mol/1 (Figure 3) . A consistent increase was observed in each animal. In the least responsive rabbit, glutamate increased by 56%, whereas in the most responsive, the levels increased more than 1,000%. The results of one particular experiment are shown in the insert of Figure 3 . Interestingly, with this concentration of adenosine, blood pressure and heart rate decreased by 21 ±10 mmHg and 15±8 beats/min, respectively.
Discussion
The present findings confirm previous observations that adenosine exerts excitatory cardiovascular effects in the NTS of anesthetized animals.
"
4 These effects, however, are not easily explained since in the CNS adenosine depresses the release of both excitatory 11 -14 and inhibitory neurotransmitters 32 and has a marked depressant action on the firing of neurons 33 and on synaptic transmission. 34 On the other hand, our results strongly suggest that in the NTS, adenosine exerts part of its cardiovascular effect first by activation of adenosine receptors and subsequent release of glutamate.
The hypotensive and bradycardic effect of adenosine were inhibited both by DPSPX and by glutamate receptor antagonists. On the other hand, the adenosine receptor antagonist was unable to affect the cardiovascular actions of glutamate in the NTS. This indicates that after activation of purinergic mechanisms, adenosine triggers glutamate systems that further decrease blood pressure and heart rate. Although it might be argued that adenosine could directly activate not only purinergic but also excitatory amino acid receptors in the NTS, our radioligand binding studies do not support this possibility. We have recently demonstrated that in rat brain stem, membranes that included the NTS, adenosine, and several of its analogues were unable to displace [ 3 H]L-glutamic acid. 35 Similarly, glutamate was unable to displace adenosine analogues from their binding sites in a similar experimental preparation. 35 The specificity of the adenosine-glutamate interaction was further studied with another glutamate receptor antagonist. A dose-dependent inhibition of the hypotensive and bradycardic effects of adenosine was also observed with GDEE. It is unlikely that any inhibition of adenosine action in the NTS would be fortuitously related to nonspecific effects of two structurally unrelated receptor antagonists. Alternatively, it can be argued that the changes in resting blood pressure and heart rate may alone affect the cardiovascular effects of adenosine in the NTS. For instance, the reflex decrease in heart rate evoked by KYN and GDEE could possibly blunt the subsequent bradycardic response of intra-NTS microinjection of adenosine. This possibility, however, is not supported by the following observations. First, the inhibitory effects of glutamate receptor antagonists on adenosine cardiovascular effects were present even when blood pressure and heart rate had returned to basal levels. We have observed that the hypotensive and bradycardic effects of adenosine administration do not reappear until 50 minutes after the administration of GDEE even though GDEE's initial hypertensive phase resolves much sooner (unpublished observations from our laboratory). In addition, in this study we have demonstrated that prior administration of another drug that also increases blood pressure and decreases heart rate did not affect adenosine actions in the NTS (see below). Finally, if a decrease in basal heart rate would be expected to abolish the bradycardic response to adenosine, an increase in basal blood pressure would be expected to potentiate the hypotensive effects. Our present results clearly indicate that the hypotensive effects of adenosine are inhibited by prior administration of KYN or GDEE.
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ADO (M) FIGURE 3. Graphs show changes in glutamate (GLU) leveb in nucleus tractus solitarius (NTS) of anesthetized rabbits by adenosine (ADO) perfusion through microdiafysis probes. Insert at top left shows changes in GLU concentration in diatysate samples of one experiment Arrow at point A indicates the stereotaxic implantation of the microdiafysis probe in the right NTS. Probes have polycarbonate-polyether copotymeric membranes with a molecular cut-off of 20,000 da. Point at the 60-minute mark represents GLU level at the end of the stabilization period. Horizontal bar on top of point B indicates the basal period in which
On the other hand, it is not clear which subtype of glutamate receptor is involved in adenosine actions in the NTS. In these studies we used GDEE and KYN as their pharmacological profile has been extensively studied. Whereas KYN is a broad-spectrum excitatory amino acid receptor antagonist, GDEE is a preferential quisqualate receptor antagonist. 36 Our results with GDEE would appear to indicate the involvement of a non-NMDA excitatory amino acid receptor. Because specificity on the subtype of receptors is probably lost with microinjection of high doses of the antagonists, final characterization will require the use of more specific NMDA and non-NMDA receptor antagonists. For instance, recent "in vitro" studies in the NTS, using more selective non-NMDA receptor antagonists, have indicated that excitatory sensory afferent synaptic transmission in this nucleus is mediated by a neurotransmitter acting at non-NMDA receptors. 37 In these studies we also approached the possibility that glutamate receptor antagonists in the NTS would inhibit the cardiovascular effects of nonrelated purinergic substances. As with adenosine and glutamate, microinjection of nicotine in the NTS evoked a decrease in blood pressure and heart rate. 38 These actions, however, were not affected by prior administration of KYN. This indicates that the inhibitory effect of excitatory amino acid receptor antagonists on adenosine and glutamate does not extend to chemically unrelated substances. Furthermore, this result clearly indicates that the actions of KYN in the NTS are not explained by a local anesthetic effect.
A variety of potential neuromodulators have been identified in the NTS. In addition to glutamate and adenosine, other agents including angiotensin, catecholamines, acetylcholine, and opioid peptides are known to reduce blood pressure and heart rate when microinjected into the NTS. 25 -39 - 41 Furthermore, the putative inhibitory neurotransmitter glycine also has been reported to exert hypotensive and bradycardic responses in the NTS 42 that in contrast to the present results, seemed to be mediated by cholinergic systems. 43 We attempted to elucidate whether some of these systems could also be involved in the final cardiovascular response of intra-NTS injections of adenosine. Since KYN and GDEE administration increase resting blood pressure, in these studies we selected specific receptor antagonists that have a similar cardiovascular action. Among neurotransmitter antagonists, only yohimbine 44 and saralasin 25 have been reported to have a pressor effect after intra-NTS microinjection. In the present results, when compared with GDEE or KYN, both the adrenergic (yohimbine) and the angiotensin (saralasin) receptor antagonist evoked a modest pressor effect and did not inhibit the effects of intra-NTS administration of adenosine. Overall this supports the specificity of the glutamate-adenosine interaction. It can be argued, however, that we used a single dose of yohimbine (0.5 nmol) that was lower than the doses of glutamate receptor antagonists. Unfortunately, the dose of yohimbine used in these studies was circumscribed by yohimbine's limited solubility in the 0.01N HC1 vehicle. More importantly, however, previous studies have demonstrated that this dose of yohimbine inhibits the cardiovascular response to a 2 -adrenergic stimulation.
-45
Saralasin was also unable to antagonize the effects of adenosine in the NTS. In earner studies, 25 we demonstrated that this dose of saralasin (0.11 nmol) completely antagonized the cardiovascular effects of intra-NTS administration of angiotensin II without affecting the actions of this peptide in other brain nuclei. Moreover, in preliminary studies in three normotensive rats we have observed that the hypotensive (-28 ±7 mmHg) and bradycardic (-35 ±15 beats/ min) effects of adenosine in the NTS were not significantly affected (-21±6 mm Hg and -30±14 beats/ min for blood pressure and heart rate, respectively) by prior administration of 25 nmol saralasin (a dose that closely approached the one used for KYN). The interpretation of this, however, is complicated by the potential agonistic effects of saralasin on angiotensin II receptors.
With the microdialysis technique, we directly tested the hypothesis that adenosine could alter glutamate levels in the NTS. Due to methodological restrictions in the NTS of rat, we opted for the use of rabbits, in which similar cardiovascular effects of both adenosine and glutamate have been observed (unpublished observations from our laboratory). Basal glutamate concentration was approximately 16 /tmol/1. This value is comparable to that previously reported in rabbit hippocampus 46 and slightly higher than that reported in rat striatum 47 (0.5-0.7 /nM) or rat cerebral cortex 48 (1.3 /u,M). In contrast to other studies in which adenosine inhibited or decreased the release of several neurotransmitters (see below), perfusion of 10~3 M of adenosine through the microdialysis probe markedly increased glutamate levels as reflected by glutamate content in the perfusate. These results strongly suggest that adenosine exerts part of its cardiovascular effect by release of glutamate from the NTS.
Adenosine and its analogues have been shown to decrease the release of glutamate in slices of rat dentate gyms, 14 hippocampal pyramidal cells, and hippocampal slices. 11 In addition, adenosine is also able to depress the release of inhibitory neurotransmitters in several brain regions. 13 -32 These observations have suggested that adenosine has a "universal" depressor effect in the CNS. However, our present results in the NTS (which are the first to demonstrate an increase in glutamate release by adenosine) and studies by others documenting an increase of dopamine 49 and acetylcholine 50 by purines, seriously challenge this concept and indicate that regional brain differences are present. In these last two reports, it was shown that activation of the adenosine receptor subtype A^ increases the release of striatal dopamine 49 or acetylcholine. 50 A recent study indicated that adenosine has biphasic (both inhibitory and excitatory) effects on postsynaptic potentials recorded in the granular cell layer of hippocampal slices. 51 Perhaps of greater relevance to our investigations are the studies by Barraco and collaborators 52 that show the hypotensive and bradycardic effects of purinergic substances in the NTS are mediated by the adenosine receptor subtype A2,. In view of these results, it is tempting to speculate that activation of A 2 receptors increases the release of neurotransmitters in some brain areas. In the NTS, our results could be explained by activation of A2, receptors and subsequent release of glutamate that in turn decreases blood pressure and heart rate.
An alternative explanation for the present results is that in the NTS, adenosine inhibits the release of an inhibitory substance that in turn attenuates glutamate release. Substances such as GABA 15 -17 or taurine 53 could affect cardiovascular function in the NTS and potentially, glutamate release. In preliminary studies we have observed that perfusion of 10~3 M of adenosine through the microdialysis probe does not affect taurine or glycine concentrations in the NTS (unpublished observations from our laboratory). Because of assay sensitivity, we have heretofore been unable to measure reliable levels of GABA in the same samples. Nevertheless, we are currently exploring this possibility using more sensitive assays. On the other hand, adenosine could affect glutamate metabolism, for instance, by inhibition of uptake mechanisms. In the CNS, uptake of glutamate into glial cells maintains the extracellular concentration of this excitatory amino acid below neurotoxic levels. Factors such as pathological rises in extracellular potassium are known to inhibit glutamate uptake. 54 The effects of adenosine on this and related glutamate clearance mechanisms are unknown.
In summary, our results indicate that adenosine has excitatory effects on cardiovascular activity in the NTS. These effects seem to be mediated by activation of glutamatergic systems. It remains to be established if adenosine directly releases glutamate in the NTS, acts through inhibition of an unidentified inhibitory substance on glutamate release, or affects glutamate uptake systems.
